Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer

Cancer Research

Volumn 58, Issue 23, 1998, Pages 5348-5353

  Markl, Isabel D C ^a   Jones, Peter A ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER CELL CULTURE; CELL CYCLE; CELL IMMORTALIZATION; CELL TRANSFORMATION; DNA BINDING; EXON; GENE MUTATION; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATOR GENE;

DNA METHYLATION; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; GENES, P53; GENES, RETINOBLASTOMA; HUMANS; MUTATION; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0032403183     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713-723, 1998.
2. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK 4. Nature (Lond.), 366: 704-707, 1993.
3. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
4. ARF. Cell, 91: 649-659, 1997.
5. Zhang, Y., Xiong, Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92: 725-734, 1998.
6. ARF. Proc. Natl. Acad. Sci. USA, 94: 669-673, 1997.
7. Velculescu, V. E., and El-Deiry, W. S. Biological and clinical importance of the p53 tumor suppressor gene. Clin. Chem., 42: 858-868, 1996.
8. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. Regulation of p53 stability by Mdm2. Nature (Lond.), 387: 299-303, 1997.
9. Chen, J., Marechal, V., and Levine, A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol., 13: 4107-4114, 1993.
10. Wu, X., Bayle, J. H., Olson, D., and Levine, A. J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 7: 1126-1132, 1993.
11. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
12. Levine, A. J., Wu, M. C., Chang, A., Silver, A., Attiyeh, E. F., Lin, J., and Epstein, C. B. The spectrum of mutations at the p53 locus. Ann. NY Acad. Sci., 768: 111-128, 1995.
13. Reddy, E. P., Reynolds, R. K., Santos, E., and Barbacid, M. A point mutation is responsible for the aquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature (Lond.), 300: 149-152, 1982.
14. Shaulian, E., Zauberman, A., Ginsberg, D., and Oren, M. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol., 12: 5581-5592, 1992.
15. Slingerland, J. M., Jenkins, J. R., and Benchimol, S. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. EMBO J., 12: 1029-1037, 1993.
16. Laird, P. W., Zijderveld, A., Linders, K., Rudnicki, M. A., Jaenisch, R., and Berns, A. Simplified mammalian DNA isolation procedure. Nucleic Acids Res., 19: 4293, 1991.
17. Gonzalgo, M. L., and Jones, P. A. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res., 25: 2529-2531, 1997.
18. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E., Smith-Sørensen, B., Montesano, R., and Harris, C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res., 22: 3551-3555, 1994.
19. Spruck, C. H., III, Gonzalez-Zulueta, M., Shibata, A., Simoneau, A. R., Lin, M. F., Gonzales, F., Tsai, Y. C., and Jones, P. A. p16 gene in uncultured tumors. Nature (Lond.), 370: 183-184, 1994.
20. Buchman, V. L., Chumakov, P. M., Ninkina, N. N., Samarina, O. P., and Georgiev, G. P. A variation in the structure of the protein-coding region of the human p53 gene. Gene (Amst.), 70: 245-252, 1988.
21. Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Tornout, J. M., and Jones, P. A. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531-4535, 1995.
22. Gonzalgo, M. L., Hayashida, T., Bender, C. M., Pao, M. M., Tsai, Y. C., Gonzales, F. A., Nguyen, H. D., Nguyen, T. T., and Jones, P. A. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res., 58: 1245-1252, 1998.
23. ARF. Cell, 91: 555-558, 1997.
24. Spruck, C. H., III, Ohneseit, P. F., Gonzalez-Zulueta, M., Esrig, D., Miyao, N., Tsai, Y. C., Lerner, S. P., Schmütte, C., Yang, A. S., Cote, R., Dubeau, L., Nichols, P., Hermann, G. G., Steven, K., Horn, T., Skinner, D. G., and Jones, P. A. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54: 784-788, 1994.
25. Cordon-Cardo, C., and Reuter, V. E. Alterations of tumor suppressor genes in bladder cancer. Semin. Diagn. Pathol., 14: 123-132, 1997.
26. Fujimoto, K., Yamada, Y., Okajima, E., Kakizoe, T., Sasaki, H., Sugimura, T., and Terada, M. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res., 52: 1393-1398, 1992.
27. Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Frye, C., Eeles, R., Orlow, I., Lacombe, L., Ponce-Castaneda, V., Lianes, P., Latres, E., Skolnick, M., Cordon-Cardo, C., and Kamb, A. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am. J. Pathol., 146: 1199-1206, 1995.
28. Yeager, T. R., DeVries, S., Jarrard, D. F., Kao, C., Nakada, S. Y., Moon, T. D., Bruskewitz, R., Stadler, W. M., Meisner, L. F., Gilchrist, K. W., Newton, M. A., Waldman, F. M., and Reznikoff, C. A. Overcoming cellular senescence in human cancer pathogenesis. Genes Dev., 12: 163-174, 1998.
29. Matlashewski, G. J., Tuck, S., Pim, D., Lamb, P., Schneider, J., and Crawford, L. V. Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell. Biol., 7: 961-963, 1987.
30. Storey, A., Thomas, M., Kalita, A., Harwood, C., Gardiol, D., Mantovani, F., Breuer, J., Leigh, I. M., Matlashewski, G., and Banks, L. Role of a p53 polymorphism in the development of human papillomavirus associated cancer. Nature (Lond.), 393: 229-234, 1998.
31. CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol., 16: 859-867, 1996.
32. Gottlieb, T. M., and Oren, M. p53 in growth control and neoplasia. Biochim. Biophys. Acta, 1287: 77-102, 1996.
33. Ko, L. J., and Prives, C. p53: puzzle and paradigm. Genes Dev., 10: 1054-1072, 1996.